Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Ann Oncol. 2019 Nov 1;30(11):1677-1681. doi: 10.1093/annonc/mdz404.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms*
  • Chemotherapy, Adjuvant
  • Genomics
  • Humans
  • Patient Reported Outcome Measures
  • Tamoxifen*

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen

Associated data

  • ClinicalTrials.gov/NCT03065621